Short answer
Abbott Laboratories (ABT) filed an 8-K current report with the SEC on October 21, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q3 2026 operating results announced October 21, 2026, with detailed figures in Exhibit 99.1.
Abbott Laboratories 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 operating results announced October 21, 2026, with detailed figures in Exhibit 99.1
- Abbott highlighted adjusted net earnings excluding acquisition, legal, restructuring, regulatory and tax-related items
- Non-GAAP results also exclude intangible amortization, improving visibility into recurring operating performance
- Investors should compare adjusted results with GAAP earnings because excluded items can materially affect reported profitability
Item EX-99.1 · Exhibit EX-99.1
- Q3 sales $13.013B, up 14.5% reported and 7.0% comparable, led by Diagnostics comparable growth of 6.4%
- Adjusted diluted EPS $1.42, up 9.2%, while GAAP EPS fell to $0.53 after $1.557B of specified charges
- Exact Sciences acquisition drove Diagnostics reported growth to 46.7%, versus 6.4% comparable growth excluding acquisition timing effects
- Full-year comparable sales growth outlook approximately 6.0%, with adjusted EPS guidance tightened to $5.50 to $5.55
- Product approvals expand growth opportunities, including Libre Duo, TactiFlex Duo, Amulet 360 and SimpleScreen CRC
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Abbott Laboratories 8-K filings
Get the next ABT 8-K as it lands
Follow ABT for push alerts, or ask the research agent what this filing means.